Literature DB >> 31723362

Correlation of Early-Phase F-18 Florapronal PET with F-18 FDG PET in Alzheimer's Disease and Normal Brain.

Jieun Jeong1,2, Young Jin Jeong1,2, Kyung Won Park2,3, Do-Young Kang1,2.   

Abstract

PURPOSE: F-18 florapronol (FPN) is the commercially recognized beta-amyloid positron emission tomography (PET) radiotracer in Korea. This study compared the early F-18 florapronol PET with F-18 fluorodeoxyglucose (FDG) PET between healthy controls (HC) and Alzheimer's dementia (AD) patients.
METHODS: A total of 29 subjects (15 HC and 14 AD subjects) underwent F-18 FPN PET and F-18 FDG PET. F-18 FDG PET image was acquired from 30 to 60 min and F-18 FPN PET for 0 to 10 min. F-18 FPN and F-18 FDG images were spatially normalized with transformation matrices obtained from individual CT images and standardized uptake value ration (SUVR) from cerebellum area, and the global mean was calculated using PMOD 3.6. Pearson's correlation coefficients between F-18 FDG and early F-18 FPN for predefined cortical brain regions were calculated.
RESULTS: We compared the F-18 FDG and F-18 FPN for SUVR of a specific region in global mean normalization and cerebellum normalization, and most of the correlation coefficient was higher in global mean normalization. In global mean normalization, the correlation coefficient for SUVR of HC was higher than that of AD in all brain regions.
CONCLUSIONS: Early F-18 FPN study can be used as a proxy marker for the F-18 FDG PET. © Korean Society of Nuclear Medicine 2019.

Entities:  

Keywords:  Alzheimer’s disease; Dual time; F-18 FDG; F-18 florapronol

Year:  2019        PMID： 31723362      PMCID： PMC6821898          DOI： 10.1007/s13139-019-00612-y

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN： 1869-3474


  9 in total

1.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers.

Authors:  Clifford R Jack; David S Knopman; William J Jagust; Ronald C Petersen; Michael W Weiner; Paul S Aisen; Leslie M Shaw; Prashanthi Vemuri; Heather J Wiste; Stephen D Weigand; Timothy G Lesnick; Vernon S Pankratz; Michael C Donohue; John Q Trojanowski
Journal:  Lancet Neurol       Date:  2013-02       Impact factor: 44.182

2.  Additional Value of Early-Phase 18F-FP-CIT PET Image for Differential Diagnosis of Atypical Parkinsonism.

Authors:  Soyoung Jin; Minyoung Oh; Seung Jun Oh; Jungsu S Oh; Sang Ju Lee; Sun Ju Chung; Jae Seung Kim
Journal:  Clin Nucl Med       Date:  2017-02       Impact factor: 7.794

3.  Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual-Time-Window Acquisition Protocol.

Authors:  Santiago Bullich; Henryk Barthel; Norman Koglin; Georg A Becker; Susan De Santi; Aleksandar Jovalekic; Andrew W Stephens; Osama Sabri
Journal:  J Nucl Med       Date:  2017-11-24       Impact factor: 10.057

4.  Relationships among local functional activity, energy metabolism, and blood flow in the central nervous system.

Authors:  L Sokoloff
Journal:  Fed Proc       Date:  1981-06

5.  Usefulness of Dual-Point Amyloid PET Scans in Appropriate Use Criteria: A Multicenter Study.

Authors:  Fermín Segovia; Manuel Gómez-Río; Raquel Sánchez-Vañó; Juan Manuel Górriz; Javier Ramírez; Eva Triviño-Ibáñez; Cristóbal Carnero-Pardo; María Dolores Martínez-Lozano; Pablo Sopena-Novales
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

6.  Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases.

Authors:  Sonja Daerr; Matthias Brendel; Christian Zach; Erik Mille; Dorothee Schilling; Mathias Johannes Zacherl; Katharina Bürger; Adrian Danek; Oliver Pogarell; Andreas Schildan; Marianne Patt; Henryk Barthel; Osama Sabri; Peter Bartenstein; Axel Rominger
Journal:  Neuroimage Clin       Date:  2016-10-08       Impact factor: 4.881

7.  Relative cerebral flow from dynamic PIB scans as an alternative for FDG scans in Alzheimer's disease PET studies.

Authors:  Débora E Peretti; David Vállez García; Fransje E Reesink; Tim van der Goot; Peter P De Deyn; Bauke M de Jong; Rudi A J O Dierckx; Ronald Boellaard
Journal:  PLoS One       Date:  2019-01-17       Impact factor: 3.240

8.  Regional differences in the coupling between resting cerebral blood flow and metabolism may indicate action preparedness as a default state.

Authors:  Ruben C Gur; J Daniel Ragland; Martin Reivich; Joel H Greenberg; Abass Alavi; Raquel E Gur
Journal:  Cereb Cortex       Date:  2008-06-04       Impact factor: 5.357

Review 9.  A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers.

Authors:  Clifford R Jack; David A Bennett; Kaj Blennow; Maria C Carrillo; Howard H Feldman; Giovanni B Frisoni; Harald Hampel; William J Jagust; Keith A Johnson; David S Knopman; Ronald C Petersen; Philip Scheltens; Reisa A Sperling; Bruno Dubois
Journal:  Neurology       Date:  2016-07-01       Impact factor: 9.910
  9 in total
  2 in total

1.  Tau Imaging: New Era of Neuroimaging for Alzheimer's Disease.

Authors:  Jae Seung Kim
Journal:  Nucl Med Mol Imaging       Date:  2020-07-27

Review 2.  [Recent Updates on PET Imaging in Neurodegenerative Diseases].

Authors:  Yu Kyeong Kim
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2022-05-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.